Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients. Results from a planned interim analysis of the phase III JAVELIN Ovarian 100 tria...
Original Article: Merck/Pfizer’s Bavencio flunks second ovarian cancer trial